KR20170078868A - 항바이러스 치료 - Google Patents

항바이러스 치료 Download PDF

Info

Publication number
KR20170078868A
KR20170078868A KR1020177017713A KR20177017713A KR20170078868A KR 20170078868 A KR20170078868 A KR 20170078868A KR 1020177017713 A KR1020177017713 A KR 1020177017713A KR 20177017713 A KR20177017713 A KR 20177017713A KR 20170078868 A KR20170078868 A KR 20170078868A
Authority
KR
South Korea
Prior art keywords
compound
formula
combination
pharmaceutically acceptable
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177017713A
Other languages
English (en)
Korean (ko)
Inventor
마크 리차드 언더우드
Original Assignee
비이브 헬쓰케어 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170078868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 비이브 헬쓰케어 컴퍼니 filed Critical 비이브 헬쓰케어 컴퍼니
Publication of KR20170078868A publication Critical patent/KR20170078868A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020177017713A 2010-01-27 2011-01-24 항바이러스 치료 Ceased KR20170078868A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
US61/298,589 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167025050A Division KR101883750B1 (ko) 2010-01-27 2011-01-24 항바이러스 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187018909A Division KR101964923B1 (ko) 2010-01-27 2011-01-24 항바이러스 치료

Publications (1)

Publication Number Publication Date
KR20170078868A true KR20170078868A (ko) 2017-07-07

Family

ID=44319704

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177017713A Ceased KR20170078868A (ko) 2010-01-27 2011-01-24 항바이러스 치료
KR1020187018909A Active KR101964923B1 (ko) 2010-01-27 2011-01-24 항바이러스 치료
KR1020127022254A Active KR101830715B1 (ko) 2010-01-27 2011-01-24 Hiv 감염을 치료하기 위한 약학적 조합물
KR1020167025050A Active KR101883750B1 (ko) 2010-01-27 2011-01-24 항바이러스 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187018909A Active KR101964923B1 (ko) 2010-01-27 2011-01-24 항바이러스 치료
KR1020127022254A Active KR101830715B1 (ko) 2010-01-27 2011-01-24 Hiv 감염을 치료하기 위한 약학적 조합물
KR1020167025050A Active KR101883750B1 (ko) 2010-01-27 2011-01-24 항바이러스 치료

Country Status (45)

Country Link
US (13) US20120295898A1 (enExample)
EP (6) EP3351249A1 (enExample)
JP (9) JP2013518107A (enExample)
KR (4) KR20170078868A (enExample)
CN (2) CN105311033B (enExample)
AP (1) AP3551A (enExample)
AU (1) AU2011209788C1 (enExample)
BR (1) BR112012018670A2 (enExample)
CA (4) CA2967453C (enExample)
CL (1) CL2012002080A1 (enExample)
CO (1) CO6602152A2 (enExample)
CR (1) CR20120423A (enExample)
CY (6) CY1116509T1 (enExample)
DK (4) DK3494972T3 (enExample)
DO (2) DOP2012000205A (enExample)
EA (4) EA025176B1 (enExample)
EC (1) ECSP12012106A (enExample)
ES (4) ES2688925T3 (enExample)
FI (2) FI3494972T3 (enExample)
FR (2) FR18C1043I2 (enExample)
HK (1) HK1250335A1 (enExample)
HR (4) HRP20150770T1 (enExample)
HU (6) HUE026849T2 (enExample)
IL (5) IL221007A (enExample)
LT (5) LT2932970T (enExample)
LU (1) LUC00090I2 (enExample)
MA (1) MA34002B1 (enExample)
ME (2) ME03058B (enExample)
MX (4) MX2012008774A (enExample)
MY (3) MY202778A (enExample)
NO (2) NO2932970T3 (enExample)
NZ (4) NZ627824A (enExample)
PE (2) PE20121524A1 (enExample)
PH (3) PH12012501537A1 (enExample)
PL (4) PL2531027T3 (enExample)
PT (4) PT3494972T (enExample)
RS (4) RS57728B1 (enExample)
SG (3) SG10201509476RA (enExample)
SI (4) SI2531027T1 (enExample)
SM (4) SMT201800594T1 (enExample)
TN (1) TN2012000376A1 (enExample)
TR (1) TR201807704T4 (enExample)
UA (1) UA105556C2 (enExample)
WO (1) WO2011094150A1 (enExample)
ZA (1) ZA201205586B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3494972T (pt) 2010-01-27 2024-02-12 Viiv Healthcare Co Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
AU2013336491B2 (en) 2012-10-23 2018-08-02 Cipla Limited Pharmaceutical antiretroviral composition
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2956123A1 (en) * 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (enExample) 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
UA117499C2 (uk) 2013-09-27 2018-08-10 Мерк Шарп Енд Доум Корп. Заміщені похідні хінолізину, які можна використовувати як інгібітори інтегрази віл
IN2014MU00916A (enExample) 2014-03-20 2015-09-25 Cipla Ltd
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP6603306B2 (ja) 2014-07-29 2019-11-06 レツク・フアーマシユーテイカルズ・デー・デー ドルテグラビルナトリウムの新規な水和物
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN110790773A (zh) 2015-04-02 2020-02-14 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
EP3334419A1 (en) * 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
KR20250004136A (ko) * 2017-10-13 2025-01-07 비이브 헬쓰케어 컴퍼니 이중층 제약 정제 제제
PL3938047T3 (pl) 2019-03-22 2022-11-07 Gilead Sciences, Inc. Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
WO2021142150A1 (en) * 2020-01-09 2021-07-15 University Of Washington Long-acting therapeutic agent combinations and methods thereof
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
US12421235B2 (en) 2020-09-30 2025-09-23 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
EP1063888A1 (en) 1998-03-27 2001-01-03 The Regents of the University of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
EP1255510B3 (en) 2000-01-31 2009-03-04 Cook Biotech, Inc. Stent valves
EP1377556B1 (en) 2001-04-10 2007-04-04 Pfizer Limited Pyrazole derivatives for treating hiv
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
NZ535817A (en) 2002-06-27 2006-11-30 Medivir Ab Synergistic interaction of abacavir and alovudine
NZ540728A (en) * 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4859676B2 (ja) * 2004-02-11 2012-01-25 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害剤
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
CA2562713A1 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
EP2332538A1 (en) * 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
KR20070043043A (ko) 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
DE602005023360D1 (de) 2004-09-17 2010-10-14 Idenix Pharmaceuticals Inc Phosphoindole als HIV-Inhibitoren
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP3187225B1 (en) 2005-04-28 2022-01-05 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
CA2610029A1 (en) 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a quinoline compound and other hiv infection therapeutic agents
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
SG170795A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
ME01617B (me) * 2006-01-20 2014-09-20 Janssen R&D Ireland Dugotrajno tretiranje hiv-infekcije s tcm278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
NZ573887A (en) 2006-07-21 2012-02-24 Gilead Sciences Inc Antiviral protease inhibitors
BRPI0717511A2 (pt) 2006-09-29 2013-11-19 Idenix Pharmaceuticals Inc Composto puro, composição farmacêutica, métodos para tratar uma infecção por hiv, para prevenir uma infecção por hiv, para inibir a replicação de hiv, e, uso de um composto
LT2487163T (lt) 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
WO2008103899A1 (en) 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
US8334295B2 (en) 2007-06-29 2012-12-18 Korea Research Institute Of Chemical Technology Pyrimidine derivatives as HIV reverse transcriptase inhibitors
CA2692331A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SI2175857T1 (sl) * 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
CN101990534A (zh) 2007-11-01 2011-03-23 Uab研究基金会 治疗和预防病毒感染
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
CN101981047A (zh) * 2008-01-03 2011-02-23 Viro化学制药公司 新的羽扇烷衍生物
JP2011508747A (ja) 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のｃ−２１ケトルパン誘導体、それらの調製および使用
ES2555209T3 (es) 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
US8217034B2 (en) * 2008-07-25 2012-07-10 Shionogi & Co., Ltd. Chemical compounds
PT3617194T (pt) 2008-12-11 2023-11-27 Shionogi & Co Processos e intermediários para inibidores carbamoilpiridona da integrase do vih
CA2744019C (en) * 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
PT3494972T (pt) 2010-01-27 2024-02-12 Viiv Healthcare Co Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS SUITABLE FOR ANTIVIRAL ACTIVE SUBSTANCES, COMPOSITIONS AND METHOD OF USE THEREOF
BR112013025368A8 (pt) 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame

Also Published As

Publication number Publication date
HUE040554T2 (hu) 2019-03-28
JP2022071126A (ja) 2022-05-13
US20250017939A1 (en) 2025-01-16
US20150238496A1 (en) 2015-08-27
KR20180078358A (ko) 2018-07-09
JP7724619B2 (ja) 2025-08-18
NZ601319A (en) 2014-08-29
NZ627827A (en) 2016-02-26
LTPA2018013I1 (lt) 2018-11-12
US20160199379A1 (en) 2016-07-14
US20210401850A1 (en) 2021-12-30
JP6268386B2 (ja) 2018-01-31
EA201690872A3 (ru) 2016-12-30
PH12018502489A1 (en) 2020-06-15
ME03058B (me) 2019-01-20
PT2531027E (pt) 2015-09-16
CA2967453A1 (en) 2011-08-04
PH12016500195B1 (en) 2021-08-04
US11234985B2 (en) 2022-02-01
FR24C1024I2 (fr) 2025-06-27
KR101883750B1 (ko) 2018-07-31
EP2531027A1 (en) 2012-12-12
JP2021091705A (ja) 2021-06-17
CA3003988A1 (en) 2011-08-04
LTPA2024516I1 (enExample) 2024-06-25
US20170119777A1 (en) 2017-05-04
JP2013518107A (ja) 2013-05-20
IL281959A (en) 2021-05-31
NZ627826A (en) 2016-01-29
IL267658A (en) 2019-08-29
EP3494972B1 (en) 2023-12-13
CY1126771T1 (el) 2025-05-09
EP4316599A2 (en) 2024-02-07
CY2018029I1 (el) 2019-07-10
JP2017008087A (ja) 2017-01-12
IL281959B (en) 2021-12-01
PT2932970T (pt) 2018-06-08
MX2012008774A (es) 2012-08-17
NO2932970T3 (enExample) 2018-08-18
SI2932970T1 (en) 2018-07-31
FR18C1043I1 (enExample) 2018-11-30
ES2670811T3 (es) 2018-06-01
EP3127542B1 (en) 2018-08-22
ME02182B (me) 2015-10-20
NO2018036I1 (no) 2018-10-15
RS54123B1 (sr) 2015-12-31
HRP20150770T1 (hr) 2015-08-28
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
EP2531027B1 (en) 2015-05-06
KR20120128640A (ko) 2012-11-27
DK2932970T3 (en) 2018-05-28
AU2011209788C1 (en) 2014-08-28
CY2024017I2 (el) 2025-05-09
HUS2400017I1 (hu) 2024-06-28
JP2016145204A (ja) 2016-08-12
SI3127542T1 (sl) 2018-11-30
EA037601B1 (ru) 2021-04-20
ECSP12012106A (es) 2013-05-31
AU2011209788A1 (en) 2012-08-16
PL2531027T3 (pl) 2016-01-29
PE20121524A1 (es) 2012-12-03
PT3127542T (pt) 2018-11-26
CA2967453C (en) 2018-07-17
EA032868B1 (ru) 2019-07-31
TN2012000376A1 (en) 2014-01-30
KR101964923B1 (ko) 2019-04-02
PH12016500195A1 (en) 2016-12-05
JP2019167371A (ja) 2019-10-03
HK1209629A1 (en) 2016-04-08
EP3127542A1 (en) 2017-02-08
EP2531027A4 (en) 2013-07-03
CO6602152A2 (es) 2013-01-18
US20180098992A1 (en) 2018-04-12
SG10201707183TA (en) 2017-10-30
DK2531027T3 (en) 2015-07-20
IL267658B (en) 2021-04-29
IL245182B (en) 2018-04-30
CY1120457T1 (el) 2019-07-10
SG10201509476RA (en) 2015-12-30
PL3127542T3 (pl) 2019-03-29
CN105311033A (zh) 2016-02-10
CN102791129B (zh) 2015-09-30
EA201892277A1 (ru) 2019-03-29
LT3494972T (lt) 2024-03-12
JP2023085431A (ja) 2023-06-20
DK3127542T3 (en) 2018-11-12
WO2011094150A1 (en) 2011-08-04
EA025176B1 (ru) 2016-11-30
IL257267A (en) 2018-03-29
CR20120423A (es) 2012-11-22
LT2932970T (lt) 2018-06-25
AP3551A (en) 2016-01-18
US20200230147A1 (en) 2020-07-23
NZ627824A (en) 2016-02-26
HUE065569T2 (hu) 2024-06-28
HUE037812T2 (hu) 2018-09-28
EP2932970A1 (en) 2015-10-21
HUS1800042I1 (hu) 2018-11-28
CY1116509T1 (el) 2017-03-15
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
US10426780B2 (en) 2019-10-01
FR18C1043I2 (fr) 2019-10-11
DOP2021000147A (es) 2022-01-16
CA2787691A1 (en) 2011-08-04
LUC00090I2 (enExample) 2019-01-08
RS57728B1 (sr) 2018-12-31
PH12012501537A1 (en) 2018-02-07
KR101830715B1 (ko) 2018-04-04
MX367937B (es) 2019-09-12
IL221007A0 (en) 2012-09-24
DK3494972T3 (da) 2024-01-29
EA202190473A3 (ru) 2021-12-31
MA34002B1 (fr) 2013-02-01
ES2688925T3 (es) 2018-11-07
EP4316599A3 (en) 2024-04-10
HRP20181531T1 (hr) 2018-11-16
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
US20170079982A1 (en) 2017-03-23
US20170216284A1 (en) 2017-08-03
US20180200254A1 (en) 2018-07-19
BR112012018670A2 (pt) 2018-02-06
MY207233A (en) 2025-02-07
CN105311033B (zh) 2019-05-07
SMT201800594T1 (it) 2019-01-11
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
MX356891B (es) 2018-06-19
MY202778A (en) 2024-05-21
SI3494972T1 (sl) 2024-03-29
US20120295898A1 (en) 2012-11-22
CA3003988C (en) 2020-01-07
SI2531027T1 (sl) 2015-08-31
KR20160111536A (ko) 2016-09-26
US20170281636A1 (en) 2017-10-05
TR201807704T4 (tr) 2018-06-21
UA105556C2 (uk) 2014-05-26
CY1121040T1 (el) 2019-12-11
HRP20180855T1 (hr) 2018-06-29
EP2932970B1 (en) 2018-03-21
EA201690872A2 (ru) 2016-08-31
EA202190473A2 (ru) 2021-06-30
LTC3494972I2 (enExample) 2025-11-10
EP3351249A1 (en) 2018-07-25
SMT201500177B (it) 2015-09-07
SMT202400063T1 (it) 2024-03-13
EA201290583A1 (ru) 2013-04-30
IL245182A0 (en) 2016-06-30
CY2024017I1 (el) 2025-05-09
AU2011209788B2 (en) 2014-02-06
MX367938B (es) 2019-09-12
CA3060290A1 (en) 2011-08-04
JP2018127473A (ja) 2018-08-16
PT3494972T (pt) 2024-02-12
LT3127542T (lt) 2018-11-26
PL2932970T3 (pl) 2018-08-31
FIC20240016I1 (fi) 2024-05-31
CA3060290C (en) 2022-07-12
PL3494972T3 (pl) 2024-05-27
CL2012002080A1 (es) 2012-11-30
CA2787691C (en) 2018-07-17
ES2969969T3 (es) 2024-05-23
LTC2932970I2 (lt) 2022-04-25
MY188334A (en) 2021-11-30
HK1179522A1 (en) 2013-10-04
HK1250335A1 (en) 2018-12-14
FI3494972T3 (fi) 2024-03-01
US20160339033A1 (en) 2016-11-24
HUE026849T2 (en) 2016-08-29
AP2012006445A0 (en) 2012-08-31
SMT201800290T1 (it) 2018-07-17
RS65183B1 (sr) 2024-03-29
CN102791129A (zh) 2012-11-21
ES2543066T3 (es) 2015-08-14
DOP2012000205A (es) 2012-10-15
CY2018029I2 (el) 2019-07-10
EP3494972A1 (en) 2019-06-12
JP2025131664A (ja) 2025-09-09

Similar Documents

Publication Publication Date Title
JP7724619B2 (ja) 抗ウイルス療法
AU2017268621C1 (en) Antiviral therapy
AU2014202404B2 (en) Antiviral therapy

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170627

Application number text: 1020167025050

Filing date: 20160909

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170719

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170801

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180406

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170801

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180702

Application number text: 1020167025050

Filing date: 20160909

PJ0201 Trial against decision of rejection

Patent event date: 20180702

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180406

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2018101002836

Request date: 20180702

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101002836; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180702

Effective date: 20191104

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20191104

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180702

Decision date: 20191104

Appeal identifier: 2018101002836

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2020201001052; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20191104

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2020201001052

Request date: 20200103

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2020201001052; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200103

Effective date: 20201016

PJ1302 Judgment (patent court)

Patent event date: 20201020

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20200103

Decision date: 20201016

Appeal identifier: 2020201001052

Appeal kind category: Appeal against decision to decline refusal